Home/Filings/4/0001181431-14-035075
4//SEC Filing

Transcept Pharmaceuticals Inc 4

Accession 0001181431-14-035075

CIK 0001178711operating

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 6:50 PM ET

Size

27.3 KB

Accession

0001181431-14-035075

Insider Transaction Report

Form 4
Period: 2014-10-30
Singh Nikhilesh N
SVP & Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2014-10-30$21.59/sh+11,758$253,83212,147 total
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-305,9500 total
    Exercise: $82.56Exp: 2020-01-14Common Stock (5,950 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-3010,0000 total
    Exercise: $48.84Exp: 2023-01-07Common Stock (10,000 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-309,5830 total
    Exercise: $19.20Exp: 2023-07-15Common Stock (9,583 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-3016,7910 total
    Exercise: $5.61Exp: 2016-03-15Common Stock (16,791 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-304,8330 total
    Exercise: $82.44Exp: 2021-02-02Common Stock (4,833 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-303,5000 total
    Exercise: $33.72Exp: 2019-02-12Common Stock (3,500 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-306,4580 total
    Exercise: $16.20Exp: 2021-08-24Common Stock (6,458 underlying)
  • Disposition to Issuer

    Common Stock (right to buy)

    2014-10-305,0000 total
    Exercise: $81.12Exp: 2022-02-01Common Stock (5,000 underlying)
Holdings
  • Common Stock

    (indirect: See footnote)
    24
  • Common Stock

    (indirect: See footnote)
    6,517
Footnotes (11)
  • [F1]Shares received in exchange for the cancellation of all outstanding stock options in connection with the merger of Paratek Pharmaceuticals, Inc. ("Paratek") into a wholly owned subsidiary of the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger and Reoganization ("Merger Agreement") by and among Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC, and Paratek, dated June 30, 2014.
  • [F10]The option vests in forty-eight equal monthly installments beginning on February 7, 2013.
  • [F11]The option vests in forty-eight equal monthly installments beginning on August 15, 2013.
  • [F2]Pursuant to terms of the Merger Agreement, immediately prior to the effective time of the Merger: each outstanding option to purchase Issuer's common stock, whether vested or unvested, with an exercise price lower than the Issuer Closing Price (as defined therein), which is $21.588, was cancelled and exchanged for a number of shares of Issuer's common stock calculated by dividing (i) the product of (a) the total number of shares of Issuer's common stock previously subject to such option and (b) the excess of the Issuer Closing Price over the exercise price of such option by (ii) the Issuer Closing Price; and (B) certain outstanding options to purchase Issuer's common stock, whether vested or unvested, with an exercise price higher than the Issuer Closing Price, were cancelled and exchanged for a number of shares of Issuer's common stock calculated by dividing a fixed dollar amount for the Reporting Person by the Issuer Closing Price.
  • [F3]Number of shares accounts for the effect of a reverse stock split of Issuer's common stock at a ratio of one new share for every twelve shares outstanding effective just prior to the effective time of the Merger (the "stock split").
  • [F4]Shares held directly by the Reporting Person's spouse.
  • [F5]Shares held directly by the Singh Family Trust (the "Family Trust") for which Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
  • [F6]Represents the adjusted stock option exercise price reflecting the Stock Split.
  • [F7]Fully exercisable.
  • [F8]The option vests in forty-eight equal monthly installments beginning March 2, 2011.
  • [F9]The option vests in forty-eight equal monthly installments beginning on March 1, 2012.

Issuer

Transcept Pharmaceuticals Inc

CIK 0001178711

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001178711

Filing Metadata

Form type
4
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 6:50 PM ET
Size
27.3 KB